IMR Press / FBL / Volume 25 / Issue 4 / DOI: 10.2741/4829

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Resveratrol reverts Streptozotocin-induced diabetic nephropathy
Show Less
1 Department of Nephrology, The First people’s Hospital of Wenling and The Affiliated Wenling Hospital of Wenzhou Medical university. Wenling, 317500, Zhejiang, P. R. China
Front. Biosci. (Landmark Ed) 2020, 25(4), 699–709;
Published: 1 January 2020
(This article belongs to the Special Issue Leader sequences of coronavirus are altered during infection)

Diabetes causes diabetic nephropathy (DN) which is associated with increased morbidity and mortality in diabetic patients. We tested whether Resveratrol (Res) reverses the systemic effect of Streptozotocin (STZ) induced diabetes and DN. Res treatment opposed the effect of STZ on kidney weight, 24 h urinary albumin excretion, blood urea nitrogen (BUN) and serum creatinine (Scr). Res also decreased DN induced mTOR/ULK1-mediated autophagy and apoptosis and significantly reduced STZ mediated lipid deposition in nephrons, likely by decreasing the levels of lipogenic related proteins (SREBP-1c, ACS) and increased lipidolysis related proteins (PPARα, CPT-1). Together, these findings show the potential of Res in prevention of diabetic nephropathy.

Renal dysfunction
Diabetic nephropathy
mTOR/ULK1 pathway
Figure 1
Back to top